Knowledge Assessment: What is a Local Safety Officer?

To ensure that SOPs, delegations, training, access and PSMF information remain aligned with actual practice To prevent any future changes to the pharmacovigilance system To make the LSO solely responsible for all implementation decisions To avoid documenting changes that may attract regulatory attention

The LSO reports only to commercial management and has no safety-specific connection The LSO may have a local functional reporting line while retaining an operational connection to Global Safety The LSO reports exclusively to the competent authority rather than the MAH The LSO works without defined reporting lines to preserve independence

One-time induction without subsequent assessment Induction, annual refresher training, inspection-readiness learning and documented scenario-based practice Training limited to commercial product knowledge Training only after an inspection finding occurs

Screen only international databases because local publications are unlikely to contain relevant cases Retain records of predefined sources, search terms, screening dates and findings Forward every article directly to the competent authority without internal assessment Record only articles that result in a confirmed signal

To allow all affiliate personnel to edit cases efficiently To control authorised access and preserve traceability of case changes To remove the need for case quality control To prevent global safety personnel from reviewing local cases

Reporter, identifiable patient, suspect product and adverse event information Patient's complete medical history, laboratory records and treatment plan Only the product name and the date on which the report was received A confirmed diagnosis, a completed causality assessment and a signed physician statement

The report can be ignored because it was not received through the preferred channel The LSO should maintain surveillance of relevant channels, capture the report and apply the standard triage workflow The report should be handled only by the marketing department The report should be deleted if the sender cannot immediately provide complete clinical details

Literature screening coverage Case entry timeliness for serious ICSRs Training currency CAPA closure timeliness

To create uniform targets that apply regardless of product or jurisdiction To provide objective evidence of performance and allow emerging compliance deterioration to be identified To replace case-level quality control with numerical scoring To ensure that only positive performance information reaches the QPPV

Correct the date in the intake log so that the report appears timely Escalate to Global Safety, Legal and Regulatory Affairs, and document the root cause and corrective action Wait for an inspector to identify the issue before taking action Submit an undated report and omit the circumstances of the delay